66
Participants
Start Date
August 26, 2021
Primary Completion Date
August 12, 2024
Study Completion Date
August 12, 2024
Tamibarotene
Tamibarotene tablets will be administered per dose and schedule specified in the arm.
Venetoclax
Venetoclax tablets will be administered per dose and schedule specified in the arm.
Azacitidine
Azacitidine injection will be administered per dose and schedule specified in the arm.
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York
CHU de Caen Normandie, Caen
Roswell Park Comprehensive Cancer Center, Buffalo
Novant Health, Charlotte
Northside, Atlanta
CHU de Bordeaux - Hôpital Haut-Lévèque, Pessac
University of Mississippi, Jackson
The Ohio State University James Cancer Hospital, Columbus
CHU Angers, Angers
CH de la Côte Basque, Bayonne
HCA Midwest Research Medical Center, Kansas City
CHU Lyon Sud, Pierre-Bénite
Hôpital Saint-Louis, Vellefaux
Centre Hospitalier de Versailles, Versailles
University of Colorado, Denver
Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver
CHU de Poitiers, Poitiers
UCLA Medical Center Division of Hematology/Oncology, Los Angeles
City of Hope, Duarte
Hôpital Avicenne Hématologie Clinique, Bobigny
Institut Gustave Roussy, Villejuif
Oregon Health & Science University, Portland
Hartford HealthCare, Hartford
Atlantic Health, Morristown
CHU Limoges, Limoges
CHU de Nantes - Hôtel Dieu, Nantes
Hôpital l'Archet- CHU de Nice, Nice
Lead Sponsor
Syros Pharmaceuticals
INDUSTRY